Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group PLC on behalf of purchasers of American Depositary Shares (ADSs) during the period from January 13, 2021, to July 28, 2024, due to alleged misleading statements regarding the safety of its cow's milk-based formula, Enfamil, for preterm infants [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt failed to inform investors that preterm infants consuming Enfamil were at an increased risk of developing necrotizing enterocolitis (NEC) [5]. - It is alleged that Reckitt's positive statements about its business and operations were materially false and misleading, lacking a reasonable basis during the class period [5]. - Investors reportedly suffered damages when the true details about the risks associated with Enfamil became public [5]. Group 2: Legal Representation - The Rosen Law Firm is representing the investors and encourages potential class members to select qualified counsel with a successful track record in securities class actions [4]. - Investors who purchased Reckitt ADSs may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the court by August 4, 2025, to represent other class members in the litigation [1][3].
RBGLY Investors Have Opportunity to Lead Reckitt Benckiser Group PLC Securities Fraud Lawsuit